NEW YORK, May 16, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free.
Halozyme Therapeutics, Inc. Analyst Notes
On May 12, 2014, Halozyme Therapeutics, Inc. (Halozyme) reported its Q1 2014 financial results with revenues of $12.0 million compared to $11.8 million in Q1 2013. Net loss totaled $26.5 million, or $0.22 per share, compared to $19.3 million, or $0.17 per share in Q1 2013. The increase in net loss is due to the Company's increased investment in clinical trials for its PEGPH20 and Hylenex® proprietary programs. "In the first quarter we saw advances in both our proprietary programs and in our partnered programs. We reported positive clinical trial results for the use of Hylenex in type 1 diabetes and for HTI-501 in cellulite." For full year 2014, the Company anticipates net cash burn to be between $45 and $55 million. The full analyst notes on Halozyme are available to download free of charge at:
MannKind Corp. Analyst Notes
On May 12, 2014, MannKind Corp. (MannKind) reported its Q1 2014 financial results. Net loss applicable to common stockholders were $52.1 million, or $0.14 per diluted share, compared to $41.0 million, or $0.15 per diluted share in Q1 2013. Research and development (R&D) expenses were $26.2 million, compared to $26.4 million in Q1 2013. No revenues were reported for the quarter by the Company. As of March 31, 2014, the Company had cash and cash equivalents of $35.8 million. The full analyst notes on MannKind are available to download free of charge at:
Arrowhead Research Corp. Analyst Notes
On May 6, 2014, Arrowhead Research Corp. (Arrowhead) reported its Q2 FY 2014 financial results (period ended March 31, 2014). Net loss attributable to Arrowhead was $13.9 million, or $0.31 per share, compared to $6.8 million, or $0.41 per share in Q2 FY 2013. Operating expenses were $11.3 million, compared to $5.4 million in Q1 2013. The Company's cash and investments of cash were $194.7 million at March 31, 2014, compared to $29.8 million on September 30, 2013. The increase in the cash balance reflects financings completed in February 2014 and October 2013, and cash inflow from exercise of warrants and stock options of $8 million. The full analyst notes on Arrowhead are available to download free of charge at:
Idera Pharmaceuticals, Inc. Analyst Notes
On May 5, 2014, Idera Pharmaceuticals, Inc. (Idera) announced the appointment of three new management team members to support the Company's progress in its development pipeline. The Company has appointed Kathryn Haviland, Vice President Rare Diseases; Joseph Lobacki, General Manager of Oncology; and Walter Strapps, Ph.D., Executive Director of RNA Therapeutics. "Kate, Joe and Walter will play a critical role as we continue to advance and expand our pipeline of oncology and orphan therapeutics derived from our proprietary nucleic acid technology platforms," said Sudhir Agrawal, D. Phil., CEO of Idera. "Each of these individuals bring a breadth of biopharmaceutical industry expertise in orphan disease product development and global commercial strategy." The full analyst notes on Idera are available to download free of charge at:
BioCryst Pharmaceuticals, Inc. Analyst Notes
On May 8, 2014, BioCryst Pharmaceuticals, Inc. (BioCryst) reported its Q1 2014 financial results with revenues of $3.5 million, down 2.7% YoY. Net loss was $10.1 million, or $0.17 per diluted share, compared to a net loss of $4.5 million, or $0.9 per diluted share in Q1 2013. Research and Development (R&D) expenses were $9.2 million, compared to $7.2 million in Q1 2013. The increase was due to higher development costs associated with the hereditary angioedema (HAE) and BCX4430 programs. "We have completed enrollment in the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4161 in patients with hereditary angioedema and we look forward to reporting results from this proof of concept trial by the end of June," said Jon P. Stonehouse, President and CEO. "In addition, we continue to advance our 2nd generation oral kallikrein inhibitors with a goal of initiating clinical trials during the first half of 2015." The Company anticipates its full year 2014 net operating cash use to be in the range of $35 to $43 million, and operating expenses to be in the range of $48 to $59 million. The full analyst notes on BioCryst are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review